Treating hyperlipidemia for the primary prevention of coronary disease: Are higher dosages of lovastatin cost-effective?

Archives of Internal Medicine

Volumn 158, Issue 4, 1998, Pages 375-381

  Perreault, Sylvie ^a   Hamilton, Vivian H ^a,b,c   Lavoie, Frédéric ^a   Grover, Steven A ^a,b  

^a MONTREAL GENERAL HOSPITAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c WASHINGTON UNIVERSITY IN ST LOUIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; MEVINOLIN; TRIACYLGLYCEROL;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMPUTER MODEL; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG COST; HUMAN; HYPERLIPIDEMIA; LIPOPROTEIN BLOOD LEVEL; PRIMARY PREVENTION; PRIORITY JOURNAL;

ANTICHOLESTEREMIC AGENTS; CORONARY DISEASE; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; LOVASTATIN; MALE; MIDDLE AGED; RISK; UNITED STATES;

EID: 0032559595     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.158.4.375     Document Type: Article

References (54)

1. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial Results, I: reduction in incidence of coronary heart disease. JAMA. 1984;251:351-364.
2. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial Results, II: the relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251:365-374.
3. Stamler J, Wentworth D, Neaton JD. Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded. JAMA. 1986;256:2823-2828.
4. Tyroler HA. Review of lipid-lowering clinical trials in relation to observational epidemiologic studies. Circulation. 1987;76:515-522.
5. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-age men with dyslipidemia. N Engl Med. 1987;317: 1237-1245.
6. Tood PA, Goa KL. Simvastatin: a review of its pharmacological properties and therapeutic potential in hypercholesterolemia. Drugs. 1990;40:583-607.
7. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimen. JAMA. 1990;264:3007-3012.
8. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-1298.
9. Bradford RH, Shear CL, Chremos AN, et al. Expanded clinical evaluation of lovastatin (EXCEL) study results, I: efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med. 1991;151:43-49.
10. Blankenhorn DH, Azen SP, Kransch DM, et al. Coronary angiographic changes with lovastatin therapy. Ann Intern Med. 1993;119:969-976.
11. Larsen ML, Illingworth DR. Drug treatment of dyslipoproteinemia. Med Clin North Am. 1994;78:225-245.
12. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344: 1383-1389.
13. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
14. Garber AM, Sox HC Jr, Littenberg B. Screening asymptomatic adults for cardiac risk factors: the serum cholesterol level. Ann Intern Med. 1989;110:622-639.
15. Grover SA, Palmer CS, Coupal L. Serum lipid screening to identify high-risk individuals for coronary death: the results of the lipid research clinics prevalence cohort. Arch Intern Med. 1994;154:679-684.
16. Garber AM, Littenberg B, Sox HC, et al. Costs and health consequences of cholesterol screening for asymptomatic older Americans. Arch Intern Med. 1991; 151:1089-1095.
17. Perreault S, Hamilton VH, Lavoie F, Grover SA. A head-to-head comparison of the cost-effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia. Cardiovasc Drugs Ther. 1996;10:787-794.
18. Schulman KA, Kinosian B, Jacobson TA, et al. Reducing high blood cholesterol level with drugs: cost-effectiveness of pharmacologic management. JAMA. 1990; 264:3025-3033.
19. Kinosian B, Eisenberg JM. Cutting into cholesterol: cost-effective alternatives for treating hypercholesterolemia. JAMA. 1988;259:2249-2254.
20. Oster G, Epstein AM. Cost-effectiveness of antihyperlipemic therapy in the prevention of coronary heart disease: the case of cholestyramine. JAMA. 1987;258: 2381-2387.
21. Goldman L, Weinstein MC, Goldman PA, Williams LW. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA. 1991;265:1145-1151.
22. Hamilton HV, Racicot FE, Zowall H, Coupal L, Grover SA. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease: estimating the benefits of increasing HDL-C. JAMA. 1995;273:1032-1038.
23. Bradford RH, Shear CL, Chremos AN, et al. Expanded clinical evaluation of lovastatin (EXCEL) study: design and patient characteristics of a double-blind, placebo-controlled study in patients with moderate hypercholesterolemia. Am J Cardiol. 1990;66:44B-55B.
24. Lovastatin Study Group II. Therapeutic response to lovastatin (Mevinolin) in non-familial hypercholesterolemia: a multicenter study. JAMA. 1986;256:2829-2834.
25. Havel RJ, Hunninghake DB, Illingworth DR, et al. Lovastatin (Mevinolin) in the treatment of heterozygous familial hypercholesterolemia: a multicenter study. Ann Intern Med. 1987;107:609-615.
26. Kannel WB, D'Agostino RB, Stepanians M, D'Agostino LC. Efficacy and tolerability of lovastatin in a six-month study: analysis by gender, age and hypertensive status. Am J Cardiol. 1990;66:1B-10B.
27. Miele NF, Page D, Phibbs CS. Controversial costs of cocaine. JAMA. 1992;267: 507-508.
28. Ontario Ministry of Health. Schedule of Benefits: Physician Services, 1989. Toronto, Ontario: Ontario Ministry of Health; 1989.
29. Régie d'Assurance Maladie du Québec. Manuel des Médecins Omnipraticiens RAMQ. Québec, Québec: Régie de l'assurance-maladie du Québec; 1989.
30. Régie d'Assurance Maladie du Québec. Manuel des Médecins Specialistes RAMQ. Québec, Québec: Régie de l'assurance-maladie du Québec; 1989.
31. Grover SA, Abrahamowicz M, Joseph L, et al. The benefits of treating hyperlipidemia to prevent coronary heart disease: estimating changes in life expectancy and morbidity. JAMA. 1992;267:816-822.
32. Abbott RD, McGee D. The probability of developing certain cardiovascular disease in eight years at specified values of some characteristics. In: Kannel WB, Wolf PA, Garrison RJ, eds. The Framingham Study: An Epidemiological Investigation of Cardiovascular Disease. Bethesda, Md: US Dept of Health, Education, and Welfare; 1987:§37. US Dept of Health, Education, and Welfare publication NIH 87-2284.
33. Statistics Canada, Health Division. Life Tables, Canada, and Provinces, 1985-1987. Ottawa, Ontario: Vital Statistics and Diseases Registries Section; 1989.
34. Kannel WB, Wolf PA, Garrison RJ. Survival following initial cardiovascular events: 30 years follow-up. In: The Framingham Study: An Epidemiological Investigation of Cardiovascular Disease. Bethesda, Md: National Heart, Lung, and Blood Institute; 1988:§35. National Heart, Lung and Blood Institute publication NIH 88-2969.
35. Grover SA, Coupal L, Hu X. Identifying adults at increased risk of coronary disease. JAMA. 1995;274:801-806.
36. Manninen V, Elo MO, Frick MH, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA. 1988;260: 641-651.
37. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ. 1994;308:367-372.
38. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
39. Garber AM, Browner WS, Hulley SB. Cholesterol screening in asymptomatic adults: revisited. Ann Intern Med. 1996;124:518-531.
40. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adults Treatment Panel II). JAMA. 1993;269:3015-3023.
41. Roberts SD, Maxwell DR, Gross TL. Cost-effective care of end-stage renal disease: a billion dollar question. Ann Intern Med. 1980;92:243-248.
42. Garner TI, Dardis R. Cost-effectiveness analysis of end-stage renal disease treatments. Med Care. 1987;25:25-34.
43. PDR Generics. 2nd ed. Montvale, NJ: Medical Economics; 1996.
44. Criqui MH. Cholesterol, primary and secondary prevention and all-cause mortality. Ann Intern Med. 1991;115:973-976.
45. Muldoon MF, Manuck SB, Matthews KA. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. BMJ. 1990;301: 309-314.
46. Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Circulation. 1992;85:37-45.
47. Frick MH, Heinonen OP, Huttunen JK, et al. Efficacy of gemfibrozil in dyslipidaemic subjects with suspected heart disease: an ancillary study in the Helsinki Heart Study Frame population. Ann Med. 1993;25:41-45.
48. Smith GD, Song F, Sheldon TA. Cholesterol lowering and mortality: the importance of considering initial level of risk. BMJ. 1993;306:1367-1373.
49. Huttunen JK, Heinonen OP, Manninen V, et al. The Helsinki Heart Study: an 8.5-year safety and mortality follow-up. J Intern Med. 1994;235:31-39.
50. Gould AL, Rossouw JE, Santanello NC, et al. Cholesterol reduction yields clinical benefit: a new look at old data. Circulation. 1995;91:2274-2282.
51. Newman TB, Hulley SB. Carcinogenicity of lipid lowering drugs. JAMA. 1996; 275:55-60.
52. Detsky AS, Naglie IG. A clinician's guide to cost-effectiveness analysis. Ann Intern Med. 1990;113:147-154.
53. Eisenberg JM. Clinical economics: a guide to the economic analysis of clinical practice. JAMA. 1989;262:2879-2886.
54. Drummond MI, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. Oxford, England: Oxford University Press; 1987.